Search Results 181-190 of 18572 for Relapse

  1. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  2. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  3. Study of ORIC-533 in Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    About this study. The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), ...

  4. Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Clinical Trials · Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma · More about research at Mayo Clinic.

  5. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  6. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, ...

  7. A Study Evaluating KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) - Mayo Clinic

    Clinical Trials · A Study Evaluating KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3) · More about ...

  8. Study of Pomalidomide for Treatment of Relapsed/Refractory Primary Central Nervous System Lymphoma and Newly Diagnosed or Relapsed/Refractory Intraocular Lymphoma - Mayo Clinic

    This phase I clinical trial aims to elucidate the maximal tolerated dose and side effects of pomalidomide in patients with relapsed or refractory primary ...

  9. A Study to Evaluate Daratumumab and Ibrutinib to Treat Relapsed / Refractory Chronic Lymphocytic Leukemia Treatment (DIRECT) - Mayo Clinic

    -Progression free survival (as determined by the IWCLL criteria) among all patients. -The overall toxicity profile of daratumumab/ibrutinib treatment in this ...

  10. Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) - Mayo Clinic

    Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) ... Patients experiencing a relapse that ...